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Weight Reduction and the Impaired Plasma-Derived
Free Fatty Acid Oxidation in Type 2 Diabetic Subjects*
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AND A. J. M. WAGENMAKERS
Departments of Human Biology, Endocrinology (B.H.R.W.), and Physiology (M.M.A.L.P.), Nutrition
Research Center, Maastricht University, 6200 MD Maastricht, The Netherlands
ABSTRACT
In a previous study the oxidation of plasma free fatty acids (FFA)
under baseline conditions and during exercise was lower in type 2
diabetic subjects compared with weight-matched controls. The
present study intended to investigate the effect of weight reduction
(very low calorie diet) on plasma FFA oxidation in seven type 2
diabetic male subjects (body fat, 37.4 6 1.2%; age, 51.3 6 3.4 yr;
plasma glucose, 7.45 6 0.48 mmol/L). Subjects underwent a 10-week
diet period. Body composition and substrate utilization during rest
and during bicycle exercise (50% of maximum aerobic capacity) were
determined before and after the diet (during weight-stable condi-
tions). FFA metabolism was studied by means of the tracer
[U-13C]palmitate. Rates of oxidation of plasma FFA were corrected
with an acetate recovery factor. Additionally, activities of mitochon-
drial enzymes and cytosolic fatty acid-binding protein were deter-
mined in biopsies from the vastus lateralis muscle before and after the
diet.
The very low calorie diet resulted in a weight loss of 15.3 kg
(110.8 6 7.4 vs. 95.5 6 5.8 kg; P , 0.01). The basal rates of appearance
and disappearance of FFA decreased as a result of diet. The rates of
appearance and disappearance of FFA during exercise were not dif-
ferent before and after diet. The oxidation of plasma-derived fatty
acids tended to decrease after diet during baseline conditions (P 5
0.10), whereas the plasma FFA oxidation during exercise was not
different before and after the diet (14.1 6 1.9 vs. 14.8 6 1.8 mmol/kg
fat-free masszmin). Skeletal muscle cytosolic fatty acid-binding pro-
tein and the activities of muscle oxidative enzymes did not signifi-
cantly change as a result of weight loss.
In conclusion, considerable weight reduction did not significantly
improve plasma-derived FFA oxidation under baseline conditions and
during exercise, suggesting that this impairment reflects a primary
defect leading to the development of type 2 diabetes mellitus rather
than resulting from the type 2 diabetic state. (J Clin Endocrinol
Metab 86: 1638–1644, 2001)
DISTURBANCES IN FATTY acid (FFA) utilization playan important role in the etiology of insulin resistance
and type 2 diabetes mellitus. The uptake and oxidation of
FFA were diminished in skeletal muscle of type 2 diabetic
subjects during postabsorptive conditions, during b-adren-
ergic stimulation (1, 2), and during exercise (3).
A diminished uptake of FFA by skeletal muscle in type 2
diabetic subjects may increase circulating FFA concentra-
tions and FFA supply to the liver, resulting in decreased
insulin binding to hepatocytes (4), diminished hepatic insu-
lin clearance, impaired insulin-mediated suppression of he-
patic glucose output (5), and increased very low density
lipoprotein-triglyceride output (6). Additionally, an im-
paired relationship between FFA uptake and oxidation may
increase im triglyceride storage, which is an important
marker of skeletal muscle insulin resistance (7).
Several mechanisms may be responsible for this impaired
ability of skeletal muscle to take up or oxidize plasma fatty
acids. In a previous study we showed a lowered rate of
appearance of FFA (RaFFA) in type 2 diabetic subjects both
under baseline conditions as well as during physical exercise
(3), suggesting that a diminished FFA availability may con-
tribute to the impaired disposal and oxidation of fatty acids.
Secondly, there are indications that muscle lipolysis may be
increased in type 2 diabetic subjects. An increased muscle
lipolysis may flood the muscle with FFA, thereby decreasing
the blood-tissue concentration gradient, which is one of the
primary determinants of plasma fatty acid uptake and oxi-
dation (8). Thirdly, there are several biochemical determi-
nants for the capacity to use fatty acids in skeletal muscle of
type 2 diabetic subjects, such as fiber type (9), a lowered
oxidative enzyme capacity (2), the activity of carnitine palmi-
toyl transferase (10), and a lowered pattern of expression of
various fatty acid-binding proteins (11).
To date, it is not known whether impairments in the path-
ways of FFA utilization in skeletal muscle are primary de-
fects or arise secondarily as a result of the diabetic state.
Impairments in the ability of the skeletal muscle to use FFA
have also been reported in obese subjects during postab-
sorptive conditions (12) and b-adrenergic stimulation (13),
suggesting that an impaired capacity to use fat may be one
of the factors linking obesity to type 2 diabetes mellitus by
promoting skeletal muscle insulin resistance and hypergly-
cemia. Additionally, persistent impairments in FFA utiliza-
tion have been previously reported after weight loss in obese
subjects (14, 15), suggesting that these defects could also be
primary to the obese state. This is consistent with the findings
that a decreased reliance on lipid oxidation is a risk factor for
weight gain (16) and for weight regain after weight loss (17).
In a recent study we found lowered plasma-derived FFA
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oxidation in type 2 diabetic subjects compared with controls
matched for age, body composition, and maximal aerobic
capacity under baseline conditions and during exercise (3).
To obtain more insight into the roles of these impairments in
the etiology of type 2 diabetes mellitus, the previously stud-
ied diabetic subjects were restudied after a period of weight
reduction. Additionally, muscle biopsies from the vastus
lateralis were taken to determine the changes in cytosolic
fatty acid-binding protein and indicators of b-oxidation and
general oxidative capacity, which previously appeared to be
lowered in type 2 diabetic subjects (2).
Subjects and Methods
Seven male subjects with type 2 diabetes mellitus were studied (age,
51.3 6 3.4 yr). The subjects were treated with diet alone (n 5 2) or with
diet together with sulfonylureas (n 5 5). Blood glucose-lowering med-
ication was stopped 2 days before the experiments and was not resumed
during the entire diet period and after diet measurements. No other
medication was used. None of the subjects had serious health problems
apart from diabetes. A normal resting electrocardiogram was a prereq-
uisite for participation. The subjects’ characteristics are indicated in
Table 1. All subjects engaged in sports for no more than 3 h a week, and
none had a physically demanding job. The study protocol was approved
by the medical ethical review committee of Maastricht University. In-
formed written consent was obtained from all subjects.
Experimental design
Before and after the diet period, measurements were made of body
composition, maximal aerobic power, insulin sensitivity, markers of FFA
transport and oxidation in muscle biopsies, and FFA kinetics. For de-
termining FFA kinetics during exercise, all subjects participated in two
stable isotope experiments in random order. In one study whole body
fatty acid metabolism was studied during baseline conditions and dur-
ing 1-h cycling exercise at 50% of the predetermined maximum aerobic
capacity (VO2max) during continuous iv infusion of the stable isotope
tracer [U-13C]palmitate (protocol 1). The fraction of 13CO2 recovered in
breath during iv infusion of the stable isotope tracer [1,2-13C]acetate
(acetate recovery factor) was determined in a separate experiment (pro-
tocol 2). This acetate recovery factor was used to correct tracer estima-
tions of plasma fatty acid oxidation during [U-13C]palmitate infusion for
label fixation into products of the citric acid cycle and in the bicarbonate
pool and has previously been extensively validated (18–20).
Diet period
The total diet intervention period lasted 10 weeks. During the first 4
weeks of the diet period the subjects followed a very low calorie diet
(Modifast, Novartis Nutrition, Breda, The Netherlands) of 2 MJ/day, which
provided 52 g/day protein, 50 g/day carbohydrate, 7 g/day fat, and 1.3
g/day sodium and a micronutrient content that meets the Dutch recom-
mended daily allowances. In the fifth week subjects were allowed to replace
one sachet per day with an energy-restricted meal (dinner), which was
increased to two energy-restricted meals/day in week 6. In the seventh and
eighth weeks subjects consumed an energy restricted diet of 4.2 MJ/day.
During weeks 9–10 subjects were in weight-stable conditions.
Body composition
Body weight was determined on an electronic scale that was accurate to
0.1 kg. Waist and hip circumference measurements to the nearest 1 cm were
made with the subjects standing upright. Body composition was deter-
mined by hydrostatic weighing with simultaneous lung volume measure-
ment (Volugraph 2000, Mijnhardt, The Netherlands). Body composition
was calculated according to the method described by Siri (21).
Maximum aerobic capacity
The maximum aerobic capacity of the subjects was determined dur-
ing an incremental protocol on a cycle ergometer. After two steps lasting
2.5 min at 0.75 and 1.5 watts/kg fat-free mass (FFM), the work load was
increased by 0.5 watts/kg FFM every 2.5 min until exhaustion. Criteria
for stopping the exercise were respiratory exchange ratio greater than
1.15 and no further increase in oxygen uptake.
Insulin sensitivity
To obtain an indication of insulin sensitivity, a short iv insulin tol-
erance test was performed, as reported previously (22). Subjects came to
the laboratory after an overnight fast. While resting supine, two cannulas
were inserted: one into an antecubital forearm vein for the administra-
tion of insulin and glucose, and the other in a dorsal hand vein for the
sampling of arterialized venous blood. At least 20 min before the test
started, the cannulated hand was placed in a warm air box, which
circulated air at 60 C. After determination of the basal glucose concen-
tration, insulin was administered in a dose of 0.1 U/kg BW. The blood
glucose concentration was determined every 2 min for 16 min using a
blood glucose analyzer (YSI, Inc., Yellow Springs, OH). Glucose was
injected at 16 min to stop the fall in blood glucose. Insulin sensitivity was
calculated from the first order constant for the disappearance rate of
glucose (Kitt), estimated from the slope of the regression line of the
logarithm of blood glucose against time during the first 4–16 min ac-
cording to the following equation: Kitt (%) 5 (0.693/t1/2) 3 100% (22).
Muscle biopsies
On a separate occasion, needle muscle biopsies were taken percutane-
ously from the vastus lateralis muscle after an overnight fast, using the
Bergstro¨m method with suction (23). The biopsies were immediately frozen
in liquid nitrogen and stored at 280 C until determination of the activities
of mitochondrial enzymes, lactate dehydrogenase and cytosolic cytosolic
fatty acid-binding protein (FABPc; see Biochemical methods).
Protocol 1: [U-13C]palmitate infusion
The subjects arrived at the laboratory after an overnight fast (of at
least 12 h) at 0800 h by car or public transport. They were studied while
resting supine on a comfortable bed in a room kept at 23–25 C. At the
beginning of the experiments, cannulas were inserted in a forearm vein
for the infusion of the stable isotope tracer and in a dorsal hand vein of
the contralateral arm for obtaining arterialized venous blood. After
placement of the catheters, the hand was placed in a warm air box where
air was circulated at 60 C. After taking background blood and breath
samples (30 min after placement of the hand in the warm air box), an
iv priming dose of 0.085 mg/kg NaH13CO3 was given. Then, a constant
rate continuous infusion of [U-13C]palmitate was started (0.008 mmol/kg
BWzmin) via a calibrated infusion pump (560 pump; IVAC, San Diego,
CA). After a 2-h baseline period (0–120 min), the rate of palmitate
infusion was doubled during the 1-h cycling exercise period (121–180
min) at 50% VO2max. The concentration of palmitate in the infusate was
measured for each experiment (see Biochemical methods), so that the exact
infusion rate could be determined. The palmitate tracer (60 mg of the
TABLE 1. Body composition, maximum aerobic capacity and
work load, and insulin sensitivity before and after weight loss
Before After
Wt (kg) 110.8 6 7.1 95.5 6 5.8a
BMI (kg/m2) 33.7 6 1.1 29.1 6 1.1a
% Body fat 37.4 6 1.2 31.2 6 1.5a
Fat mass (kg) 41.7 6 3.3 30.0 6 2.7a
Fat-free mass (kg) 69.1 6 4.2 65.4 6 3.5a
VO2 max (mL/kgFFMzmin) 36.2 6 2.9 41.3 6 2.4
Wmax (watts/kgFFMzmin) 2.67 6 0.19 3.03 6 0.17
Fasting glucose (mmol/L) 7.45 6 0.48 6.46 6 0.59b
Fasting insulin (mU/L) 17.5 6 1.7 11.4 6 1.5b
KITT (%/min)c 2.1 6 0.2 2.7 6 0.3b
Values are the mean 6 SE (n 5 7).
a P , 0.001, by paired t test.
b P , 0.05, by paired t test.
c First order constant for the disappearance rate of glucose after iv
insulin.
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potassium salt of [U-13C]palmitate, 99% enriched; Cambridge Isotope
Laboratories, Andover, MA) was dissolved in heated sterile water and
passed through a 0.2-mm pore size filter into a 5% warm human serum
albumin (Central Blood Bank, Amsterdam, The Netherlands) to make a
0.65-mmol/L solution (mean 6 sd, 0.650 6 0.025 mmol/L).
Breath, blood, and urine sampling
Five minutes before the start of infusion (background), and at 100,
110, and 120 min during the baseline period and 150, 160, 170, and 180
during exercise, breath samples were taken to determine the enrichment
of CO2 (
13C/12C ratio) in expired air. Expired air samples were obtained
by having the subjects breathe normally for 3 min into a mouthpiece,
connected to a 6.75-L mixing chamber and then collecting a breath
sample into a 20-mL Vacutainer tube. Additionally, at the above-indi-
cated time points arterialized blood samples were taken to determine the
concentrations of glucose, insulin, glycerol, O2, FFA, and palmitate as
well as the 13C/12C ratio of palmitate. During the resting period and the
last 40 min of exercise, O2 and CO2 exchanges were determined by
means of an open circuit ventilated hood system (Oxycon b; Mijnhardt,
The Netherlands). Urine was collected overnight in containers with 10
mL H2SO4 to determine nitrogen excretion to calculate the nonprotein
respiratory exchange ratio.
Protocol 2: [1,2-13C]acetate
The acetate recovery in expired air was determined in a separate
experiment of similar design during a 2-h baseline period and a 1-h
period of exercise at 50% VO2max. After collection of a background
breath sample, subjects received an iv priming dose of 0.085 mg/kg
NaH13CO3. The stable isotope tracer [1,2-
13C]acetate was continuously
infused during the baseline period, and the rate of infusion was doubled
at the start of the exercise period. The acetate tracer was dissolved into
0.9% saline to obtain a 3.46 6 0.02-mol/L solution. Acetate was infused
at a rate of 0.064 mmol/kg BWzmin to obtain the same 13C infusion rate
per time unit as for the palmitate tracer. Breath samples were taken at
similar time points as during the palmitate infusion.
Biochemical methods
Blood samples were collected in ethylenediamine tetraacetate-
containing tubes on ice and were immediately centrifuged at 4 C, and
the plasma was put in liquid nitrogen until storage at 280 C. Breath
samples were analyzed for 13C/12C ratio by injecting 20 mL of the
gaseous head space into a gas chromatography (GC) continuous flow
isotope ratio mass spectrometer (Finnigan MAT 252, Bremen, Germany).
For determination of plasma palmitate and total FFA kinetics, FFA were
extracted from plasma, isolated by thin layer chromatography, and
derivatized to their methyl esters. Isotope enrichment of palmitate was
determined by GC-isotope ratio mass spectrometry after on-line com-
bustion of fatty acids to CO2 (Finnigan MAT 252). Palmitate concen-
trations were determined on an analytical GC with ion flame detection
using heptadecanoic acid as internal standard, and on the average, it
comprised 24 6 1% of the total FFA concentration. Total plasma FFA,
glucose, glycerol, lactate, and infusate acetate concentrations were mea-
sured using standard enzymatic techniques automated on the Cobas
Fara centrifugal analyzer at 340 nm (for FFA: FFA-C test kit, Wako
Chemicals, Neuss, Germany; for glucose: Roche Unikit III, Hoffman-
LaRoche Inc., Basel, Switzerland; for glycerol and acetate: Roche Mo-
lecular Biochemicals, Mannheim, Germany). Plasma insulin was mea-
sured using a specific double antibody RIA for human insulin (Kabi
Pharmacia, Uppsala, Sweden). Nitrogen concentrations in urine were
measured using an elemental analyzer (type CN-O-Rapid; Heraeus,
Hanau, Germany).
The muscle biopsies were homogenized in ice-cold Tris-ethylenedi-
amine tetraacetate buffer at pH 7.4. The homogenates were subsequently
sonicated four times for 15 s each time and centrifuged at 10,000 3 g for
2 min at 4 C to remove cell debris. The tissue content of heart-type or
muscle-type FABPc in skeletal muscle was measured by means of a
newly developed enzyme-linked immunosorbent assay (Hycult Bio-
technology, Uden, The Netherlands), using recombinant human FABP
as standard (24). Citrate synthase was determined according to the
method of Shepherd and Garland (25), whereas 3-hydroxyacyl-coen-
zyme A dehydrogenase was assayed according to the method of Berg-
meyer (26).
Calculations
The metabolic rate was calculated from oxygen consumption and
carbon dioxide production (VO2 and VCO2) according to the equation
of Weir (27). Carbohydrate and fat oxidation rates were calculated from
VO2, VCO2, and urinary nitrogen excretion (28). Protein oxidation (cal-
culated from nitrogen excretion) was assumed to be similar during the
overnight fasted state and exercise.
TABLE 2. Circulating concentrations of metabolites during baseline conditions and during a 60-min period of moderate intensity exercise
before and after weight loss
Baseline
Exercise
30 min 40 min 50 min 60 min Average exercise
(50,60 min)
Glucose (mmol/L)
Before 7.45 6 0.48 6.83 6 0.45 6.56 6 0.39 6.39 6 0.45 7.13 6 0.93 6.76 6 0.61a
After 6.46 6 0.59b 5.72 6 0.44 5.80 6 0.45 5.75 6 0.44 5.78 6 0.45 5.77 6 0.59a,b
FFA (mmol/L)
Before 679 6 83 679 6 83 744 6 81 608 6 107 748 6 139 678 6 121
After 583 6 120 528 6 97 636 6 156 775 6 155 850 6 164 813 6 159c
Glycerol
Before 113 6 10 208 6 24 268 6 90 308 6 43 292 6 58 300 6 50c
After 70 6 8b 188 6 36 214 6 31 238 6 33 265 6 29 251 6 31a
Insulin (mU/mL)
Before 17.5 6 4.8 13.7 6 1.2 13.3 6 1.7 13.1 6 1.8 13.3 6 1.7 13.2 6 1.7c
After 11.4 6 1.5b 9.2 6 1.0 9.2 6 1.2 8.6 6 1.0 8.1 6 1.0 8.4 6 1.0b,c
Norepinephrine (pg/mL)
Before 343 6 34 1243 6 153 1320 6 151 1325 6 169 1322 6 160d
After 249 6 22 1028 6 96 1107 6 100 1187 6 108 1147 6 103d
Epinephrine (pg/mL)
Before 32 6 3 59 6 8 68 6 12 78 6 17 73 6 14c
After 35 6 3 70 6 7 88 6 13 105 6 23 96 6 18a
Values are the mean 6 SE (n 5 7).
a P , 0.01, average exercise vs. baseline.
b P , 0.05, baseline and exercise, before vs. after.
c P , 0.05, average exercise vs. baseline.
d P , 0.001, average exercise vs. baseline.
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Tracer calculations
Fatty acid oxidation was calculated by converting the rate of triglyc-
eride oxidation (grams per min) to its molar equivalent, with the as-
sumption that the average molecular weight of triglyceride was 860
g/mol and with a tripled molar rate of triglyceride oxidation because
each molecule contains 3 mol fatty acids.
During the last 20 min of the baseline period (110 and 120 min), a
physiological and isotopic steady state was present, and therefore,
Steele’s equation for steady state was used to calculate the palmitate flux
[rates of appearance or disappearance (Ra or Rd)], as reported previ-
ously (2). During the exercise period nonsteady state equations for the
RaFFA and RdFFA were used (29).
The RaFFA was calculated by dividing the Ra of palmitate by the
fractional contribution of palmitate to the total FFA concentration.
The fractional recovery of the acetate label in breath CO2 (acetate
recovery factor) and the percentage of infused [U-13C]palmitate oxidized
were calculated as described previously (2).
Plasma-derived fatty acid oxidation (micromoles per min) was cal-
culated as: oxidation 5 RdFFA 3 % of infused palmitate tracer oxidized.
The fatty acid oxidation from plasma triglycerides and intraorgan
triglycerides (muscle and adipose tissue) was calculated as: sum of
triglyceride 2 derived fatty acid oxidation 5 total fatty acid oxidation 2
plasma-derived fatty acid oxidation.
Statistics
Data are presented as the mean 6 se. Differences before and after diet
were analyzed with Student’s paired t test. Statistical significance was
set at P , 0.05.
Results
Body composition, maximal aerobic capacity, and
insulin sensitivity
As indicated in Table 1, there was a significant decrease in
body weight, fat mass, and FFM as a result of the very low
calorie diet. The 15.3-kg BW loss can be accounted for 78%
by loss of fat mass and 22% by loss of FFM. The subjects were
restudied after a 2-week weight-stable period (average
weight change over this period, 20.5 6 0.3; range, 20.7 to
20.2 kg). Maximal aerobic capacity and maximal work load,
as determined during the incremental cycling protocol, were
not significantly different before compared with after the
diet. Basal glucose and insulin concentrations significantly
decreased after the diet. Also, there was a significant increase
in insulin sensitivity as indicated by the increased insulin
sensitivity index.
Arterialized concentrations of circulating metabolites
and hormones
Glucose concentrations decreased during exercise both
before and after the diet (Table 2). Glucose concentrations
were lower after the diet compared with before under base-
line conditions as well as during exercise. Basal FFA con-
centrations were not significantly different before and after
the diet (P 5 0.11). FFA concentrations did not change as a
result of exercise before the diet, whereas exercise induced a
significant increase in FFA concentrations after the diet. Basal
glycerol concentrations decreased as a result of the diet,
whereas glycerol concentrations during exercise were not
different before and after the diet. Insulin concentrations
decreased during exercise and were lower after compared
with before the diet. Basal norepinephrine concentrations
were lower after the diet, and norepinephrine concentrations
during exercise were similar before and after the diet. Epi-
nephrine concentrations increased during exercise, whereas
epinephrine concentrations were not different before and
after the diet.
Whole body indirect calorimetry
Whole body energy expenditure and total carbohydrate
and fat oxidation reached a plateau after 40 min of exercise
(data not shown). The mean values of the last 20 min of the
baseline and exercise periods, expressed per FFM, are indi-
cated in Fig. 1. Energy expenditure increased 4- to 5-fold as
a result of exercise. There were no significant differences in
FIG. 1. Whole body energy expenditure (EE) and carbohydrate
(CHO) and fat oxidation during baseline conditions and during mod-
erate intensity exercise before and after weight reduction in obese
type 2 diabetic subjects. For all variables, average exercise vs. base-
line, P , 0.001.
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energy expenditure or fat and carbohydrate oxidation before
and after the diet throughout the experiment.
Stable isotope infusion
Acetate recovery increased gradually during baseline con-
ditions and reached a plateau during exercise (Fig. 2). Acetate
recovery during exercise was higher after compared with
before the diet (P , 0.05). Baseline RaFFA and RdFFA de-
creased as a result of the diet, and these variables were
similar during exercise before and after the diet (Fig. 3).
Figure 4 shows the different components of fatty acid oxi-
dation before and after the diet. Baseline and total fatty acid
oxidation during exercise were not significantly different
between the groups (Fig. 4, upper panel). The oxidation of
plasma-derived FFA tended to decrease after the diet during
baseline conditions (P 5 0.10), whereas plasma-derived FFA
oxidation during exercise was not different before and after
the diet. Also, nonplasma-derived FFA oxidation was not
significantly different before and after the diet.
Muscle biopsies
The concentration of FABPc tended to increase after the
diet (before vs. after, 1.83 6 0.44 vs. 2.08 6 0.34 mg/g total
protein), but did not reach statistical significance. Also, the
concentration of 3-hydroxyacyl-coenzyme A dehydrogenase
(70.6 6 12.8 vs. 89 6 13 U/g protein) and citrate synthase
(104 6 18 vs. 111 6 14 U/g protein) were slightly higher after
the diet, but were not statistically different compared with the
prediet measurements.
There was a positive correlation between the amount of
weight lost and the increase in FABPc (Fig. 5, upper panel).
Also, the change in FABPc positively correlated to the change
in baseline plasma-derived FFA oxidation (Fig. 5, lower
panel).
Discussion
Impairments in fatty acid utilization are of importance in
the etiology of type 2 diabetes mellitus. In a previous study
we showed that plasma-derived fatty acid oxidation is low-
ered in type 2 diabetic subjects under baseline conditions as
well as during physical exercise (3). The type 2 diabetic
subjects of the previous study were restudied after weight
reduction during weight stable conditions. Weight reduction
resulted in a 15-kg body weight loss (percent body fat before
vs. after, 37.4% vs. 31.2%) and a considerable increase in
insulin sensitivity.
Plasma-derived FFA oxidation
Both under baseline conditions as well as during physical
exercise the lowered plasma-derived FFA oxidation did not
significantly improve as a result of diet. These data suggest
that these impairments in FFA utilization may be important
factors leading to type 2 diabetes mellitus rather than merely
resulting from the type 2 diabetic state. A lowered capacity
to use fat during basal conditions has been implicated pre-
viously in the etiology of obesity and insulin resistance (14–
17). In this respect it is tempting to speculate that a primary
defect in the ability to oxidize fat may cause an imbalance
between muscle FFA uptake and oxidation and may thereby
increase im triglyceride storage, which is strongly associated
with insulin resistance (7). However, care has to be taken in
interpreting the whole body plasma FFA oxidation during
baseline conditions, because this reflects both skeletal muscle
and liver FFA oxidation, the main fatty acid consumers dur-
ing postabsorptive conditions (30). Thus, we cannot exclude
that an improvement in baseline muscle FFA oxidation did
FIG. 2. Fractional 13C label recovery of [1,2-13C]acetate during base-
line conditions (90–120 min) and during moderate intensity exercise
(121–160 min) before and after weight reduction in obese type 2
diabetic subjects. Exercise, before vs. after: *, P , 0.05. For average
exercise (170 and 180 min) vs. baseline (120 min): P , 0.001.
FIG. 3. RaFFA and RdFFA under baseline conditions and during
moderate intensity exercise before and after weight reduction in obese
type 2 diabetic subjects. Baseline, before vs. after: *, P , 0.05. For all
variables, average exercise vs. baseline: P , 0.001.
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occur but was offset at the whole body level by a decrement
in liver FFA oxidation. As skeletal muscle is largely respon-
sible for the increase in fat oxidation during exercise (31), the
present data show that the ability of skeletal muscle to ox-
idize plasma FFA during exercise does not significantly im-
prove after the diet. Future studies have to show in what
stage in the transition from the normal glucose tolerant to the
type 2 diabetic state these disturbances develop.
Underlying mechanisms
One of the determining factors for muscle FFA utilization
may be the FFA supply to muscle, which is an important
driving force for fatty acid uptake (8). RaFFA and RdFFA
were lowered in the type 2 diabetic subjects under baseline
conditions as well as during exercise. As a result of the diet,
baseline RaFFA and RdFFA decreased, whereas these pa-
rameters did not change during exercise. Thus, the lowered
FFA supply to muscle may provide an explanation for the
diminished plasma-derived FFA oxidation in type 2 diabetic
subjects.
Markers of skeletal muscle oxidative enzyme capacity and
cytosolic fatty acid transport capacity did not significantly
change after diet. However, there was a significant positive
relationship between the amount of weight lost and the in-
crease in FABPc. Also, the increase in FABPc was positively
related to the change in baseline plasma-derived FFA oxi-
dation (after vs. before). These data suggest that the ability
to maintain or increase fatty acid transport capacity may be
a determining factor in the success of a weight reduction
program in type 2 diabetic subjects, as this would maintain
or prevent the decrease in baseline plasma-derived FFA ox-
idation. Also, this correlation between increases in muscle
FABPc and changes in baseline whole body FFA utilization
(after vs. before) suggests that weight loss-induced changes
in postabsorptive FFA utilization mainly occur in skeletal
muscle. A role for FABPc in the physiological adaptations of
FIG. 4. Total fatty acid oxidation, plasma-derived fatty acid oxida-
tion, and triglyceride-derived fatty acid oxidation before and after
weight reduction in obese type 2 diabetic subjects. For total fatty acid
oxidation and plasma-derived fatty acid oxidation: average exercise
vs. baseline, P , 0.001.
FIG. 5. Relationships between the increase in FABPc as result of
weight reduction and body weight loss (upper panel) and baseline
plasma-derived FFA oxidation (after vs. before) in obese type 2 dia-
betic subjects.
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fat metabolism after energy restriction has been suggested in
obese women (32). Additionally, support for an important
role for FABPc in impairments in fat utilization comes from
a previous study (2), in which lowered muscle FABPc was
observed in skeletal muscle of type 2 diabetic subjects.
Conclusion
In conclusion, the previously reported lowered postab-
sorptive and exercise-mediated plasma FFA oxidation in
type 2 diabetic subjects did not significantly improve as a
result of weight reduction, indicating that these disturbances
may be important factors leading to the diabetic state rather
than merely resulting from diabetes. We propose that a low-
ered FFA availability, as shown by the lowered RaFFA and
RdFFA, may play an important role in this impaired FFA
utilization. Furthermore, the present data suggest that the
ability to maintain or increase muscle fatty acid transport
capacity may be a determining factor in the success of a
weight reduction program in type 2 diabetic subjects, as this
would maintain or prevent the decrease in baseline plasma-
derived FFA oxidation.
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